首页> 美国卫生研究院文献>Oncology Letters >Inhibition of cancer cell proliferation by midazolam by targeting transient receptor potential melastatin 7
【2h】

Inhibition of cancer cell proliferation by midazolam by targeting transient receptor potential melastatin 7

机译:咪达唑仑通过靶向瞬时受体电位褪黑素7抑制癌细胞增殖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Transient receptor potential melastatin 7 (TRPM7), a Ca2+-permeable channel, has been demonstrated to be present in cancer cells and involved in their growth and proliferation. The present study used midazolam, a benzodiazepine class anesthesic, to pharmacologically intervene in the expression of TRPM7 and to inhibit cancer cell proliferation. Midazolam significantly inhibited the growth and proliferation of FaDu human hypopharyngeal squamous cell carcinoma cells, concurring with the induction of G0/G1 cell cycle arrest and blockage of Rb activation. Central-type and peripheral-type benzodiazepine receptor antagonists did not abrogate proliferation inhibition by midazolam, while the specific TRPM7 agonist bradykinin reversed this effect. In addition, other benzodiazepines, diazepam and clonazepam also exhibited anti-proliferative activities. The inhibitory activity on cancer cell growth and proliferation, combined with the TRPM-dependent mechanism, reveals the anticancer potential of midazolam as a TRPM7 inhibitor and supports the suggestion that TRPM7 is a valuable target for pharmaceutical intervention.
机译:瞬时受体电位褪黑素7(TRPM7)是Ca 2 + 的可渗透通道,已被证明存在于癌细胞中并参与其生长和增殖。本研究使用了苯二氮卓类麻醉药咪达唑仑,在药理学上干预TRPM7的表达并抑制癌细胞的增殖。咪达唑仑显着抑制FaDu人下咽鳞状细胞癌细胞的生长和增殖,同时诱导G0 / G1细胞周期停滞和Rb激活受阻。中央型和外周型苯二氮卓受体拮抗剂并没有消除咪达唑仑对增殖的抑制作用,而特定的TRPM7激动剂缓激肽逆转了这一作用。另外,其他苯并二氮杂,地西epa和氯硝西am也表现出抗增殖活性。对癌细胞生长和增殖的抑制活性,结合TRPM依赖性机制,揭示了咪达唑仑作为TRPM7抑制剂的抗癌潜力,并支持TRPM7是药物干预的重要靶标的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号